NIH Awards BellBrook Labs Phase II Grant to Develop Drugs Targeting the cGAS-STING Pathway for Lupus and Related Autoimmune Diseases

cGAS Phase II Press Release Graphic
The National Institute of Allergy and Infectious Diseases (NIAID) recently awarded BellBrook Labs a $1.8 million Phase II Small Business Innovative Research (SBIR) grant to develop small molecule antagonists of cyclic GAMP synthase (cGAS). The grant will enable BellBrook to optimize their cGAS lead molecules and test their efficacy for treating lupus-related UV light sensitivity
Read more
No Comments

BellBrook Labs Receives NIH Funding for Novel Approach to Stimulating Antitumor Immunity

TREX1 Press Release Graphic
The National Cancer Institute (NCI) recently awarded BellBrook Labs a $300,000 Phase I Small Business Innovative Research (SBIR) grant to develop tools for discovering small-molecule antagonists of TREX1, a checkpoint at the top of the critical immunostimulatory STING pathway. Madison, WI – March 2021 – BellBrook Labs has been awarded a $300,000 Phase I Small
Read more
No Comments

New Publication by the Scientists at BellBrook Labs – Development of a High-Throughput Assay to Identify Inhibitors of ENPP1

Inhibitors of ENPP1 SLAS Discovery
BellBrook scientist Meera Kumar and Robert Lowery were recently published in SLAS Discovery for their work entitled Development of a High-Throughput Assay to Identify Inhibitors of ENPP1. Ectonucleotide pyrophosphatase/phosphodiesterase 1 or ENNP1 has recently become a target for cancer immunotherapy. ENNP1 hydrolyzes nucleotides such as cGAMP and ATP. Cytosolic DNA is a trigger for the
Read more
No Comments

Join Us for SLAS 2021 Virtual Conference

SLAS 2021
BellBrook Labs will be exhibiting at SLAS 2021, January 25-27. Due to the pandemic, this year’s meeting will, of course, be virtual. Although, we are sad that we won’t be able to meet with you in person this year there are still plenty of opportunities to interact. We will have a virtual booth that is
Read more
No Comments

New TR-FRET Readout Now Available with the Transcreener cGAMP cGAS Assay

New cGAS TR-FRET Assay
Launched in November 2019, the Transcreener cGAMP cGAS Assay has generated a great deal of interest in the drug discovery community. While fluorescence polarization (FP) readouts offer a stable and robust option, some researchers prefer time-resolved Förster-resonance-energy-transfer (TR-FRET) readouts for large screens. After months of development, BellBrook Labs is pleased to announce the addition of
Read more
No Comments

Previously Recorded Webinar – Streamline cGAS Inhibitor Discovery with the Transcreener® cGAS Assay

Webinar Graphic
The immune system uses the recognition of foreign nucleic acids and subsequent type I interferon production as a first line of defense in response to microbial invaders. Recent research has validated one key to this cascade, a unique cyclic dinucleotide – cGAMP. The enzyme cGAS produces this recently discovered molecular messenger. As an apoenzyme, cGAS
Read more
No Comments

Battling Autoimmune Disorders Using JAK1 Inhibitors

JAK1 Inhibitors for Autoimmune Disease
Could specific JAK1 inhibitors lead to better treatments for autoimmune disease? – The human immune response is complex with numerous cellular pathways playing a role. And, when an abnormal immune response results from one’s own body, known as an autoimmune disorder – it adds to the complexity. While we often think of celiac disease, inflammatory
Read more
No Comments

New Transcreener UDP2 Assay with a Fluorescence Intensity Readout

Transcreener Glycosyltransferase Assay Blog
BellBrook Labs scientists have developed a new universal UDP detection assay for the measurement of Glycosyltransferase activity.  The Transcreener UDP2 FI Assay extends the Transcreener platform for UDP detection by utilizing a simple fluorescence intensity (FI) output. It can be used on fluorescence readers typically found in academic and therapeutic research laboratories, as well as
Read more
No Comments

New Transcreener CD73 Assay for Discovery of Therapeutics to Enhance Tumor Immunity

cGAS Inhibitors Grant
The new Transcreener CD73 Assay measures adenosine production by CD73 in a mix-and-read format with a far-red fluorescence polarization readout. The assay will accelerate efforts to discover selective CD73 antagonists for cancer immunotherapy by enabling high throughput screening, structure-driven hit-to-lead, and mechanistic studies with the purified enzyme. Madison, WI – April 27th, 2020 – Researchers
Read more
No Comments

Recorded Webinar – Transcreener® CD73 Assay: Leveraging Nucleotide Detection to Measure Adenosine

Webinar Graphic
CD73 is a plasma membrane-bound ectonucleotidase that hydrolyzes AMP into adenosine, contributing to immunosuppression in the tumor microenvironment; it is being pursued as a promising immuno-oncology drug target. In this webinar we will present the steps involved in development of the Transcreener CD73 assay. Transcreener is a biochemical HTS assay platform based on homogenous immunodetection
Read more
No Comments